Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00341991
Status:
COMPLETED
Last Update Posted:
2020-06-30
First Post:
2006-06-19
Brief Title:
Molecular Epidemiology of Cutaneous Malignant Melanoma
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Molecular Epidemiology of Cutaneous Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This case-control study was planned to investigate the link of solar radiation with gene damage host factors and DNA repair proficiency in cutaneous malignant melanoma CMM risk The hypothesis was that impaired DNA repair proficiency is associated with an increased risk of CMM due to unrepaired DNA damage particularly in subjects with dysplastic nevi poor tanning ability or genetic susceptibility
The study was reviewed as an RO1 Grant from the National Cancer Institute in 1995 Subject enrollment which included clinical evaluation epidemiologic questionnaires and skin and blood sample collection was completed in 1999 on approximately 180 melanoma cases and 180 controls identified in Italy The study protocol and consent form both included the measurement of genetic and biochemical factors and DNA repair capacity DNA repair proficiency was measured in lymphocytes by the host cell reactivation assay and sun exposure was evaluated by means of a detailed questionaire Photographs of the back of the subjects were taken to allow nevi count Minimal erythemal dosage was measured in all subjects to estimate skin sun sensitivity 24 hours after skins UV-irradiation Skin color was ascertained on the inner side of the forearm by means of a Minolta chromometer
The aim of this protocol is to continue analysis of the biological samples already collected as originally outlined in the study protocol In particular we plan to measure polymorphisms in genes that may lead to susceptibility to melanoma Initially we will concentrate on variation in genes involved in repairing damaged DNA but plan to look at a broad group of candidate susceptibility genes
The study was reviewed as an RO1 Grant from the National Cancer Institute in 1995 Subject enrollment which included clinical evaluation epidemiologic questionnaires and skin and blood sample collection was completed in 1999 on approximately 180 melanoma cases and 180 controls identified in Italy The study protocol and consent form both included the measurement of genetic and biochemical factors and DNA repair capacity DNA repair proficiency was measured in lymphocytes by the host cell reactivation assay and sun exposure was evaluated by means of a detailed questionaire Photographs of the back of the subjects were taken to allow nevi count Minimal erythemal dosage was measured in all subjects to estimate skin sun sensitivity 24 hours after skins UV-irradiation Skin color was ascertained on the inner side of the forearm by means of a Minolta chromometer
The aim of this protocol is to continue analysis of the biological samples already collected as originally outlined in the study protocol In particular we plan to measure polymorphisms in genes that may lead to susceptibility to melanoma Initially we will concentrate on variation in genes involved in repairing damaged DNA but plan to look at a broad group of candidate susceptibility genes
Detailed Description:
The original case-control study was planned to investigate the link of solar radiation with gene damage host factors including also genetic variants and DNA repair proficiency in cutaneous malignant melanoma CMM risk in subjects from the Mediterranean area characterized by a wide range of pigmentary characteristics and intense sun exposure This study was reviewed and funded as an R01 grant from the National Cancer Institute in 1995 Subject enrollment which included clinical evaluation epidemiologic questionnaires and skin and blood sample collection was completed in 1999 on approximately 180 melanoma cases and 180 controls identified in Italy The study protocol and consent form both included the measurement of genetic and biochemical factors and DNA repair capacity DNA repair proficiency was measured in lymphocytes by the host cell reactiviation assay and sun exposure was evaluated by means of a detailed questionnaire Minimal erythemal dosage was measured in all subjects to estimate skin sun sensitivity 24 hours after skins UVirradiation Skin color was ascertained on the inner side of the forearm by means of a minolta chromometer
The aim of this protocol was to continue the analysis of the biological samples and data already collected as originally outlined in the study protocol However the original sample size was small and precluded specific analyses of gene-environment interaction crucial for the understanding of the etiology of melanoma We have identified other collaborators willing to share their data and sample with us to increase the power for statistical analyses We obtained approval amendments to 02-C-N035 approved in November 2006 September 2008 December 2010 and June 2011 to use the DNA samples and data collected in four studies conducted by investigators at the University of LAquila Italy University of Genoa Italy Istituto Valenciano de Oncologia Valencia Spain and the New York University School of Medicine respectively We have obtained approval with stipulations in August 2014 to also include samples and data collected from the Papa Giovanni XXII Hospital in Bergamo Italy and the University of Athens Greece We are now responding to the stipulations and asking to further include samples from the University of Padua and the Hospital Clinic of Barcelona within the same study
We are currently analyzing genes in several pathways including pigmentation DNA repair immune-related functions and those involved in the transition from nevi to melanoma genes in the cell cycle telomere signaling pathways etc With the additional samples we plan to conduct a GWAS analysis of melanoma in Mediterranean countries and a molecular analysis of melanoma tissue lesions for an improved classification of the disease and its association with melanoma progression
The aim of this protocol was to continue the analysis of the biological samples and data already collected as originally outlined in the study protocol However the original sample size was small and precluded specific analyses of gene-environment interaction crucial for the understanding of the etiology of melanoma We have identified other collaborators willing to share their data and sample with us to increase the power for statistical analyses We obtained approval amendments to 02-C-N035 approved in November 2006 September 2008 December 2010 and June 2011 to use the DNA samples and data collected in four studies conducted by investigators at the University of LAquila Italy University of Genoa Italy Istituto Valenciano de Oncologia Valencia Spain and the New York University School of Medicine respectively We have obtained approval with stipulations in August 2014 to also include samples and data collected from the Papa Giovanni XXII Hospital in Bergamo Italy and the University of Athens Greece We are now responding to the stipulations and asking to further include samples from the University of Padua and the Hospital Clinic of Barcelona within the same study
We are currently analyzing genes in several pathways including pigmentation DNA repair immune-related functions and those involved in the transition from nevi to melanoma genes in the cell cycle telomere signaling pathways etc With the additional samples we plan to conduct a GWAS analysis of melanoma in Mediterranean countries and a molecular analysis of melanoma tissue lesions for an improved classification of the disease and its association with melanoma progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 02-C-N035 | None | None | None |